GENKYOTEX’S GKT831 PREVENTS MULTIPLE COMPLICATIONS OF PORTAL HYPERTENSION IN PRECLINICAL MODEL

GENKYOTEX’S GKT831 PREVENTS MULTIPLE COMPLICATIONS OF PORTAL HYPERTENSION IN PRECLINICAL MODEL

DATA SUPPORTS THERAPEUTIC ROLE OF GKT831 IN ADVANCED LIVER FIBROSIS

  • Results published in Clinics and Research in Hepatology and Gastroenterology
  • Phase 3 trial being planned in primary biliary cholangitis

Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), the leading biopharmaceutical company in NOX therapies, today announced the publication of data in Clinics and Research in Hepatology and Gastroenterology showing that its anti-fibrotic drug candidate GKT831, prevents multiple complications of portal hypertension in a preclinical model.

For more Information,

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2019/2019-07-01_Genkyotex_GKT831_ENG_83102.pdf